NEUROCOGNITIVE DIGITAL BIOMARKES

_Mr. GREEN IS NOT ALONE

• Cases expected to triple in

2050

• Every 3 seconds someone in

the world develops dementia

+65 DIES WITH DEMENTIA

_Mr. GREEN IS NOT ALONE

+65 DIES WITH DEMENTIA

75% UNDIAGNOSEDCASES WORLDWIDE

• Cases expected to triple in

2050

• Every 3 seconds someone in

the world develops dementia

_STAGES OFALZHEIMER’S

• The progression of the disease

can be slowed by acting

quickly

MCI

Mild AD

Moderate/ Severe AD

_STAGES OFALZHEIMER’S

• The costs of AD increase with

the pathology progression

HEALTHYMILD COGNITIVE

IMPAIRMENT MILD MODERATE

U$3K U$6.5K U$16K U$29K

ALZHEIMER’S DISEASE

SEVERE

U$44K

_STAGES OFALZHEIMER’S

• The costs of AD increase with

the pathology progression

HEALTHYMILD COGNITIVE

IMPAIRMENT MILD MODERATE

U$3K U$6.5K U$16K U$29K

ALZHEIMER’S DISEASE

SEVERE

U$44KEARLY DIAGNOSE

_EARLY DETECTION

• Symptoms can be postponed

of even controlled if dementia

is diagnosed in the early stages

_EARLY DETECTION

• Symptoms must be identified

in Primary Care

PRE-SYMPTOMATIC

MCI

AD

PRIMARY CARE

_EARLY DETECTION

Quick Neurocognitive Evaluations:

• Low Sensibility

• Low Specificity

PRIMARY CARE

ACCURATELOW ACC.

SPECIALIZED PHYCISIANS

PRIMARY CARENEURO.

EVALUATION

_EARLY DETECTION

Neurocognitive Batteries:

• Up to 6 hours

• Medium-High Sensibility

• Low Specificity

• Results are subjective

NUEROCOGNITIVEBATTERY

PRIMARY CARENEURO.

EVALUATION

PRIMARY CARE

ACCURATELOW ACC.

SPECIALIZED PHYCISIANS

_EARLY DETECTION

Tools for early detection are:

• Invasive

• Costly

• Time consuming

• Complex

NUEROCOGNITIVEBATTERY

BIOMARKERS

NEUROIMAGES

PRIMARY CARENEURO.

EVALUATION

PRIMARY CARE

ACCURATELOW ACC.

SPECIALIZED PHYCISIANS

_VIEWMIND

A quick and simple tool for the

early detection of Alzheimer’s and

other dementias NUEROCOGNITIVEBATTERY

BIOMARKERS

NEUROIMAGES

PRIMARY CARENEURO.

EVALUATION

PRIMARY CARE

ACCURATELOW ACC.

SPECIALIZED PHYCISIANS

_THE PRODUCT

SHORT TERM MEMORY BINDING

(4 MIN)

READING TASK(3 MIN)

LABYRINTH(4 MIN)

N-BACK TEST(5 MIN)

• 10 minutes Eye-Tracking test

• Non-invasive, automatized

and standardized

• Series of tests to quantify

cognitive functions

• Patented algorithms

• Clinically validated

CONTROL

_READING BEHABIOUR

CONTROL ALZHEIMER’S DISEASE

_READING BEHABIOUR

_THE PRODUCT

• 10 minutes Eye-Tracking test

• Non-invasive, automatized

and standardized

• Series of tests to quantify

cognitive functions

• Patented algorithms

• Clinically validated

PRE-SYMPTOMATIC

MCI

AD

_THE PRODUCT

• 10 minutes Eye-Tracking test

• Non-invasive automatized

and standardized

• Series of tests to quantify

cognitive functions

• Patented algorithms

• Clinically validated

PRE-SYMPTOMATIC

MCI

AD

98% ACCURACY

_THE PRODUCT

• 10 minutes Eye-Tracking test

• Non-invasive automatized

and standardized

• Series of tests to quantify

cognitive functions

• Patented algorithms

• Clinically validated

PRE-SYMPTOMATIC

MCI

AD

93% ACCURACY15 YEARS

98% ACCURACY

_PROGRAM FOR DEMENTIAPREVENTIO

• Free program for the

prevention of Dementia

• Medicaments for prevention

• Non-drug assistance for

prevention

INFO@DEMENCE.LU

CONTACTCONTACT INFORMATION

MATIAS SHULZCEO

Matias.Shulz@ViewMind.com.ar+352 661 620 366